tag:blogger.com,1999:blog-35442466285833690412024-03-14T12:18:17.243-04:00Temple Rock Holdings Inc.Temple Rock Holdings Inc. (TRH) develops a wide range of business opportunities centered on emergent trends relating to the behavior of the consumer.Unknownnoreply@blogger.comBlogger76125tag:blogger.com,1999:blog-3544246628583369041.post-22418896803805710052011-06-13T14:54:00.002-04:002011-06-13T14:56:21.392-04:00<span style="font-weight: bold;">NON-ANTIBIOTIC PRODUCT FROM CHEMAPHOR INC. ENHANCES INNATE IMMUNITY IN FISH</span><br />Opens possibilities for use as a low risk, non-antibiotic, prophylactic, natural health product for maintaining health and helping protect against infectious diseases<br /><br />OTTAWA, ON., June 9, 2011 - Recently released research has shown that immunity in fish is enhanced when fed Chemaphor's proprietary mixture of fully oxidized carotenoids.<span style="text-decoration: underline;"><span style="font-weight: bold;"> </span></span><a href="http://www.thenewswire.ca/archives?tnwarchive2=release_id%3D3905"><strong><strong><strong>MORE>></strong></strong></strong></a>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-73932494460501356262011-06-01T11:34:00.001-04:002011-06-01T11:36:23.697-04:00<span style="font-weight: bold;">SYNCAPSE GEARS UP FOR RAPID GROWTH WITH ADDITIONS TO EXECUTIVE TEAM</span><span style="font-weight: bold;"><br /></span><p><strong>Five New Appointments Will Drive Growth and Deliver Social Media Management Solutions for Enterprise Clients</strong></p> <p> </p><p><strong>TORONTO, ONTARIO and NEW YORK, NEW YORK--(Marketwire - June 1, 2011) -</strong> Syncapse Corp., <a href="http://syncapse.com/">a global leader in social media management</a><a href="http://www.syncapse.com/"> for large enterprise</a>, announced today five new additions to its executive team, signaling its intention for rapid growth heading into the second half of 2011. <a href="http://www.marketwire.com/press-release/syncapse-gears-up-for-rapid-growth-with-additions-to-executive-team-1521408.htm"><strong><strong><strong><strong>MORE>></strong></strong></strong></strong></a></p>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-38619528504296501572011-06-01T11:21:00.001-04:002011-06-01T11:23:09.096-04:00<span style="font-weight: bold;">CYNAPSUS THERAPEUTICS TO PRESENT AT BIOFINANCE 2011 CONFERENCE</span><strong><br /></strong><strong>TORONTO, ONTARIO--(Marketwire - May 31, 2011) -</strong> Cynapsus Therapeutics Inc. (TSX VENTURE:CTH), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease, announced today that Anthony Giovinazzo, President and Chief Executive Officer, will present an overview of the Company at the BioFinance 2011 Conference, being held this week in Toronto. Mr. Giovinazzo will be speaking tomorrow (Wednesday, June 1<sup>st</sup>) at 3:00 p.m., at the St. Andrew's Club & Conference Centre, 150 King Street West. <a href="http://www.marketwire.com/press-release/cynapsus-therapeutics-to-present-at-biofinance-2011-conference-tsx-venture-cth-1520882.htm"><strong><strong><strong><strong>MORE>></strong></strong></strong></strong></a>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-73343035447458821712011-06-01T11:17:00.001-04:002011-06-01T11:19:20.454-04:00<span style="font-weight: bold;">CYNAPSUS ANNOUNCES RESULTS OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS</span><strong><br /></strong><strong>TORONTO, ONTARIO--(Marketwire - May 31, 2011) -</strong> Cynapsus Therapeutics Inc. (TSX VENTURE:CTH), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease, today announced the results of its Annual and Special Meeting of Shareholders held earlier in the day, on May 31, 2011. <a href="http://www.marketwire.com/press-release/cynapsus-announces-results-of-annual-and-special-meeting-of-shareholders-tsx-venture-cth-1520859.htm"><strong><strong><strong><strong>MORE>></strong></strong></strong></strong></a>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-61470569376956078302011-06-01T11:13:00.003-04:002011-06-01T11:20:18.309-04:00<span style="font-weight: bold;">BIOSIGN APPOINTS THREE NEW MEMBERS TO BOARD OF DIRECTORS</span><span class="xn-location"><br />TORONTO</span>, <span class="xn-chron">May 27, 2011</span> /CNW/ - Biosign Technologies Inc. (<b>TSXV: BIO, "Biosign"</b>) announced today the appointment to its board of directors of <span class="xn-person">Dr. Harold S. Koplewicz</span>, Jason D. Meretsky, and Former <span class="xn-person">Senator Alfonse</span> D'Amato. <p align="justify"> "We are pleased to welcome back Senator D'Amato and be joined by our new members, <span class="xn-person">Dr. Koplewicz</span> and <span class="xn-person">Mr. Meretsky</span>", said <span class="xn-person">David Silver</span>, the company's Chairman. "As Biosign embarks on an exciting period of change and growth, attracting a diverse range of leadership for our Board and management team is critical to our success". <strong><strong><strong><a href="http://www.marketwire.com/press-release/cynapsus-therapeutics-signs-term-sheet-for-c10-million-private-placement-offering-tsx-venture-cth-1519028.htm"><strong><strong><strong><strong></strong></strong></strong></strong></a><strong><strong><strong><a href="http://www.newswire.ca/en/releases/archive/May2011/27/c8312.html">MORE>></a><br /></strong></strong></strong></strong></strong></strong></p>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-16593522925803626562011-05-27T22:43:00.001-04:002011-05-27T22:46:46.570-04:00<span style="font-weight: bold;">BIOSIGN TO INTRODUCE UFIT AT AN INTERNATIONAL ENGINEERING CONFERENCE</span><span class="xn-location"><br /></span><span class="xn-location">TORONTO</span>, <span class="xn-chron">May 27, 2011</span> /CNW/ - Biosign Technologies Inc. (<b>TSXV: BIO) ("Biosign"</b>) announced today that it will introduce its latest generation medical measurement system, the UFIT® TEN-20, at the International Symposium on Medical Measurements and Applications (MeMeA), being held in <span class="xn-location">Italy</span> by the Institute of Electrical and Electronics Engineers (IEEE) on May 30-31, 2011. <a><strong><strong><strong></strong></strong></strong></a><a href="http://www.newswire.ca/en/releases/archive/May2011/27/c8134.html"><strong><strong><strong></strong></strong></strong></a><a><strong><strong><strong><strong><strong><strong><strong></strong></strong></strong></strong></strong></strong></strong></a><strong><strong><strong><a href="http://www.marketwire.com/press-release/cynapsus-therapeutics-signs-term-sheet-for-c10-million-private-placement-offering-tsx-venture-cth-1519028.htm"><strong><strong><strong><strong>MORE>></strong></strong></strong></strong></a></strong></strong></strong>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-81488021644702052982011-05-27T22:38:00.002-04:002011-05-27T22:42:38.009-04:00<span style="font-weight: bold;">JOLYON BURTON ANNOUNCES ACQUISITION OF COMMON SHARES OF CHEMAPHOR INC.</span><br /><span class="xn-location">TORONTO</span>, <span class="xn-chron">May 27, 2011</span> /CNW/ - Jolyon Burton acquired, by private placement, ownership of 2,450,000 units ("Units") of Chemaphor Inc. ("Chemaphor"). Each Unit was purchased for <span class="xn-money">$0.10</span> and consists of one common share and one-half of one common share purchase warrant in the capital of Chemaphor. <a href="http://www.newswire.ca/en/releases/archive/May2011/27/c8460.html"><strong><strong><strong><strong></strong></strong></strong></strong></a><strong><strong><strong><a href="http://www.marketwire.com/press-release/cynapsus-therapeutics-signs-term-sheet-for-c10-million-private-placement-offering-tsx-venture-cth-1519028.htm"><strong><strong><strong><strong>MORE>></strong></strong></strong></strong></a></strong></strong></strong>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-11338416678628269652011-05-25T14:18:00.001-04:002011-05-25T14:19:56.895-04:00<span style="font-weight: bold;">CYNAPSUS THERAPEUTICS SIGNS TERM SHEET FOR C$10 MILLION PRIVATE PLACEMENT OFFERING</span><strong></strong><strong><br />TORONTO, ONTARIO--(Marketwire - May 25, 2011) -</strong> Cynapsus Therapeutics Inc. (the "Company" or "Cynapsus") (TSX VENTURE:CTH) today announced that it has signed a term sheet with a Health Care / Life Sciences focused Institutional Investment Group (the "Lead Investor") to be the lead investor in a private placement offering of C$10 million of its common shares and warrants (the "Offering").<a href="http://www.marketwire.com/press-release/cynapsus-therapeutics-signs-term-sheet-for-c10-million-private-placement-offering-tsx-venture-cth-1519028.htm"><strong><strong><strong><strong>MORE>></strong></strong></strong></strong></a><a href="http://www.marketwire.com/press-release/cynapsus-therapeutics-signs-term-sheet-for-c10-million-private-placement-offering-tsx-venture-cth-1519028.htm"> </a>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-15882294904603043992011-05-17T14:21:00.001-04:002011-05-17T14:23:14.172-04:00<span style="font-weight: bold;">CHEMAPHOR INC. AVIAGEN ANIMAL HEALTH INC. UPDATE</span><br />OTTAWA, ONTARIO, May 17, 2011 - NOTE: Below is a news release that was written and released by the Prince Edward Island Department of Innovation and Advanced Learning on April 28, 2011 about Chemaphor Inc. (TSXV:CFR) and its wholly-owned subsidiary Avivagen Animal Health Inc.<br /><a href="http://www.newswire.ca/en/releases/archive/March2011/28/c7201.html"><strong><strong><strong><strong><strong><strong></strong></strong></strong></strong></strong></strong></a><a href="http://www.marketwire.com/press-release/Cynapsus-Therapeutics-Present-BIOCOM-Global-Life-Science-Partnering-Conference-TSX-VENTURE-CTH-1398297.htm"><strong><strong><strong><strong> </strong></strong></strong></strong></a><a href="http://www.theglobeandmail.com/globe-investor/news-sources/?date=20110517&archive=tnw&slug=54350"><strong><strong><strong>MORE>></strong></strong></strong></a>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-92039503579363652372011-05-17T14:07:00.000-04:002011-05-17T14:09:03.530-04:00<span style="font-weight: bold;">BIOSIGN ANNOUNCES UFIT HEALTH MONITORING STUDY</span><span style="font-weight: bold;"><br /></span><span class="xn-location">TORONTO</span>, <span class="xn-chron">May 12</span> /CNW/ - Biosign Technologies Inc. (<b>TSXV: BIO) ("Biosign)</b> announced today the initiation of a short-term study of the UFIT® biomedical system to determine the "best practices" for monitoring blood pressure and blood glucose. The study is being conducted in collaboration with McMaster University, which will use Biosign's technology to benchmark a technology framework for providing reliable and secure health information services.<br /><span class="xn-location"></span><a href="http://www.newswire.ca/en/releases/archive/March2011/28/c7201.html"><strong><strong><strong><strong><strong><strong></strong></strong></strong></strong></strong></strong></a><a href="http://www.marketwire.com/press-release/Cynapsus-Therapeutics-Present-BIOCOM-Global-Life-Science-Partnering-Conference-TSX-VENTURE-CTH-1398297.htm"><strong><strong><strong><strong> </strong></strong></strong></strong></a><strong><strong><strong><a href="http://www.newswire.ca/en/releases/archive/May2011/12/c3898.html">MORE>></a></strong></strong></strong>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-61704759840020605602011-05-02T18:05:00.002-04:002011-05-02T18:10:06.950-04:00<span style="font-weight: bold;">THERALASE TECHNOLOGIES INC. ANNOUNCES ITS YEAR END FINANCIAL RESULTS</span> - <span style="font-weight: bold;">PRIMED FOR GROWTH WITH EXCITING PROGRESS IN RESEARCH AND DEVELOPMENT</span><strong><br />TORONTO, ONTARIO--(Marketwire - May 2, 2011) -</strong> Theralase Technologies Inc. (TSX VENTURE:TLT) announces its year end 2010 financial results. Total revenue for twelve months ending December 31, 2010 at $2,040,537 compared to $2,359,855 for the same period in 2009.<strong><strong></strong></strong><br /><strong></strong><a href="http://www.marketwire.com/press-release/theralase-technologies-inc-announces-its-year-end-financial-results-tsx-venture-tlt-1508898.htm"><strong><strong><strong><strong>MORE>></strong></strong></strong></strong></a>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-39937640784834215452011-04-29T11:31:00.001-04:002011-04-29T11:33:56.468-04:00<span style="font-weight: bold;">THE CANARY SYSTEM RECEIVES HEALTH CANADA APPROVAL </span><strong><br /></strong><span><span class="maPara1"><span style="font-weight: bold;" class="maStartDate">April 28, 2011</span> -- Health Canada has approved the Canary system, an early caries mapping and detection system manufactured by <a href="http://www.thecanarysystem.com/index.php">Quantum Dental Technologies</a>, for sale in Canada. </span></span>"We've been contacted by many dental professionals wanting to know when the Canary system would be available for sale, and now that we have Health Canada's approval we are looking forward to getting the Canary system into dental offices across Canada," said President and Founder Stephen Abrams, DDS, in a press release.<a href="http://www.cynapsus.ca/news.php?article=217"><strong><strong><strong><strong></strong></strong></strong></strong></a>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-89513466812167678072011-04-29T11:24:00.001-04:002011-04-29T11:24:18.543-04:00<span style="font-weight: bold;">CYNAPSUS ANNOUNCES PROPOSED ACQUISITION OF ADAGIO PHARMACEUTICALS AND PRIVATE PLACEMENT</span><strong><br />TORONTO, ONTARIO--(Marketwire - April 26, 2011) -</strong> <a name="top">Cynapsus Therapeutics Inc. (the "Corporation" or "Cynapsus") (CTH: TSX-V) is pleased to announce that it has entered into a preliminary agreement dated April 26, 2011 with Adagio Pharmaceuticals Ltd. ("Adagio") providing for the acquisition by Cynapsus of all of the issued and outstanding shares of Adagio in a share exchange (the "Proposed Transaction")</a>. <a href="http://www.cynapsus.ca/news.php?article=217"><strong><strong><strong><strong>MORE>></strong></strong></strong></strong></a>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-34278251861361045092011-04-29T11:09:00.002-04:002011-04-29T11:18:59.678-04:00<span style="font-weight: bold;">SYNCAPSE ADDRESSES KEY PAIN POINTS FOR SOCIAL MARKETERS, ACCORDING TO FORRESTER RESEARCH, INC. REPORT</span><br /><span style="font-weight: bold;">April 20th, 2011 - </span>By Meg Sinclair, Manager, Corporate Communications - It’s time for marketers to take control of their social marketing program. Today, Forrester Research released a report that outlines the vendor landscape in the social marketing management industry. <strong></strong><strong></strong><em><strong style="font-weight: bold;"></strong></em><a href="http://www.syncapse.com/2011/04/syncapse-addresses-key-pain-points-for-social-marketers-according-to-forrester-research-inc-report/"><strong>MORE>></strong></a>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-34272535937725203772011-04-17T20:11:00.001-04:002011-04-17T20:13:23.736-04:00<span style="font-weight: bold;">CHEMAPHOR ANNOUNCES PROPOSED PRIVATE PLACEMENT</span><br /><strong>OTTAWA, ONTARIO--(Marketwire - April 15, 2011) -</strong> Chemaphor Inc. (TSX VENTURE:CFR), today announced that it is proposing to complete a non-brokered private placement resulting in gross proceeds of up to approximately $1,000,000. It is currently anticipated that the proposed private placement will be completed in April, 2011. <a href="http://www.marketwire.com/press-release/Chemaphor-Announces-Proposed-Private-Placement-TSX-VENTURE-CFR-1428554.htm"><strong><strong><strong><strong>MORE>></strong></strong></strong></strong></a>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-48121196602719815182011-04-17T20:06:00.002-04:002011-04-17T20:09:34.721-04:00<span style="font-weight: bold;">BIOWORLD INSIGHT: PARKINSON'S UPDATE: DISEASE PIPELINE RUNNING THE GAMUT</span><br /><p> April 12, 2011 - By Brian Orelli, Contributing Writer </p><p>There were roughly 40 million Americans over the age of 65 in 2010, but as the baby boomer generation continues to reach the monumental age, the number of Americans in that class is expected to increase to 70 million in 2030. <a href="http://www.cynapsus.ca/news.php?article=216"><span style="font-weight: bold; color: rgb(102, 102, 102);">MORE>></span></a></p>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-59044391479882270942011-04-17T20:04:00.002-04:002011-04-17T20:05:54.298-04:00<span style="font-weight: bold;">QUANTUM DENTAL TECHNOLOGIES RECEIVES ACA SILVERTIP AWARD FOR INNOVATION<br /></span><span>Boston, MA, April 5, 2011 - The Angel Capital Association (ACA), the trade association of leading angel investment groups in North America, announced that Quantum Dental Technologies of Toronto, Ontario, Canada is the winner of the Silvertip Luis Villalobos Award.</span> <a href="http://bostonharborangels.com/data/Quantum%20Dental%20Technologies.pdf"><strong><strong><strong><strong>MORE>></strong></strong></strong></strong></a>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-4857662956908401262011-04-17T19:56:00.002-04:002011-04-17T19:59:34.640-04:00<span style="font-weight: bold;">THE BURRILL REPORT: AN INTERVIEW WITH ANTHONY GIOVINAZZO, PRESIDENT AND CEO, CYNAPSUS THERAPEUTICS</span><br /><p> April 5, 2011</p>Cynapsus Therapeutics is a small Canadian specialty pharma trying to reinvent itself. Under Anthony Giovinazzo, who took the helm at the end of 2009, the company has a new name and new focus. It’s hoping that its reformulation of an existing treatment for Parkinson’s disease can put it on a fast path to revenue with limited investment. <a href="http://www.cynapsus.ca/news.php?article=215"><span style="font-weight: bold; color: rgb(102, 102, 102);">MORE>></span></a>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-54771406204324478712011-04-01T12:54:00.001-04:002011-04-01T12:56:22.029-04:00<span style="font-weight: bold;">BIOSIGN TECHNOLOGIES RELEASES SCALABLE ARCHITECTURE AND BEGINS SHIPPING UFIT</span><br /><p align="left"> <span class="xn-location">TORONTO</span>, <span class="xn-chron">March 31</span> /CNW/ - Biosign Technologies Inc. (<b>TSXV: BIO, "Biosign" or the "company"</b>) is providing a corporate update on recent developments. </p> Biosign has successfully migrated UFIT to its proprietary "VIMIS" (Virtual Instrumentation & Measurement Information System) architecture. This new, scalable technology platform allows for each server set to process 172,800 readings per hour and store up to 2 million readings per hour. Biosign has successfully launched the VIMIS-supported version of the UFIT Graphical User Interface and its <a href="http://myufit.com/">MyUFIT.com</a> portal. <a href="http://www.newswire.ca/en/releases/archive/March2011/31/c8355.html"><strong>MORE>></strong></a>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-11996506452838602622011-04-01T12:52:00.001-04:002011-04-01T12:53:42.179-04:00<span style="font-weight: bold;">HOSPITALS IN THE CENTRAL LHIN TO IMPLEMENT STATE OF ART SURGICAL BOOKING AND WAIT TIMES SYSTEM</span><span id="spanContent" class="plainText"><strong><br /> </strong></span><strong></strong><span id="spanContent" class="plainText">AJAX, ON: March 30, 2011 -Novari Health announced today that it is working with seven of the hospitals in the Central East LHIN to implement its web-based Surgical Access with Smart Wait™ software system in order to improve access to care and ensure that the allocation of valuable surgical resources is improved for a variety of surgical services including cataract and hip and knee surgery.</span> <em><strong style="font-weight: bold;"></strong></em><a href="http://www.novarihealth.com/CELHINAnnounce.aspx?m=4"><strong>MORE>></strong></a>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-24626376316971693472011-03-29T11:05:00.001-04:002011-03-29T11:06:57.506-04:00<span style="font-weight: bold;">INDUSTRY VETERAN CLAUDE GALIPEAU JOINS SYNCAPSE AS CHIEF SERVICE OFFICER</span><strong><br />TORONTO, ONTARIO--(Marketwire - March 29, 2011) -</strong> <strong>Syncapse Corp.,</strong> <a href="http://syncapse.com/">a global leader in social media management</a>, today announced that Mr. Claude Galipeau is joining the company as Chief Service Officer, effective April 1, 2011. Claude brings more than fifteen years of experience in digital media leadership, most recently as Senior Vice President and General Manager, Digital Media, <a href="http://www.rogersdigitalmedia.com/">Rogers Media Inc.</a> <a href="http://www.marketwire.com/press-release/Industry-Veteran-Claude-Galipeau-Joins-Syncapse-as-Chief-Service-Officer-1419046.htm"><strong><strong><strong><strong>MORE>></strong></strong></strong></strong></a>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-51722964824851629692011-03-29T10:56:00.005-04:002011-03-29T11:02:41.079-04:00<span style="font-weight: bold;">BIOSIGN TECHNOLOGIES AMENDS DynamiCARE AGREEMENT<br /></span><span class="xn-location">TORONTO</span>, <span class="xn-chron">March 28</span> /CNW/ - Biosign Technologies (TSXV: BIO) ("Biosign") and DynamiCARE AG have replaced their exclusive master distribution agreement announced on <span class="xn-chron">July 2, 2010</span> with a similar but non-exclusive distribution agreement. Under the revised agreement, DynamiCARE will have nonexclusive distribution rights to resell Biosign products in <span class="xn-location">Germany</span>, <span class="xn-location">France</span>, <span class="xn-location">Switzerland</span>, and <span class="xn-location">Austria</span> and will not be required to pay the <span class="xn-money">$2.5million</span> milestone payment or achieve the volume commitments that were required in the previous agreement to maintain exclusivity. This modification to the DynamiCARE agreement enables Biosign to move forward with other multinational distribution partners in <span class="xn-location">Europe. </span><a href="http://www.newswire.ca/en/releases/archive/March2011/28/c7201.html"><strong><strong><strong><strong><strong><strong><strong><strong></strong></strong></strong></strong></strong></strong></strong></strong></a><a href="http://www.marketwire.com/press-release/Cynapsus-Therapeutics-Present-BIOCOM-Global-Life-Science-Partnering-Conference-TSX-VENTURE-CTH-1398297.htm"><strong><strong><strong><strong>MORE>></strong></strong></strong></strong></a><br /><br /><br /><a href="http://www.cynapsus.ca/news.php?article=213"><span style="font-weight: bold; color: rgb(102, 102, 102);"></span></a>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-27420590187505869682011-03-25T10:21:00.005-04:002011-03-25T10:27:10.808-04:00<span style="font-weight: bold;">CYNAPSUS SEEKING CRO FOR STUDIES OF LEAD PD AGENT; PLANS TO FIND GLOBAL PARTNER POST COMPLETION OF PIVOTAL STUDY - CEO<br /></span><p>BioPharm Insight, March 23, 2011, Anusha Kambhampaty</p><p>Cynapsus Therapeutics (CVE:CTH) is currently engaging in discussions with CROs to help run a Phase I study of lead agent APL-130277, a sublingual formulation of apomorphine, an approved agent used to treat “off-episodes” of patients with advanced Parkinson’s disease (PD), CEO Anthony Giovinazzo said. The Phase I trial is expected to initiate this July or August and the company will likely hire the CRO by June, Giovinazzo noted. <a href="http://www.cynapsus.ca/news.php?article=213"><span style="font-weight: bold; color: rgb(102, 102, 102);">MORE>></span></a><span style="color: rgb(51, 51, 255);"> </span></p><strong><strong><strong><strong><a href="http://www.marketwire.com/press-release/Cynapsus-Therapeutics-Announces-Resignation-of-Chairman-David-Pattenden-TSX-VENTURE-CTH-1415843.htm"><strong><strong><strong><strong></strong></strong></strong></strong></a></strong></strong></strong></strong><a href="http://www.marketwire.com/press-release/Theralase-Appoints-General-Manager-for-Its-Therapeutic-Division-TSX-VENTURE-TLT-1414949.htm"><strong></strong></a>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-6963890674149052372011-03-23T12:05:00.001-04:002011-03-23T12:07:19.163-04:00<span style="font-weight: bold;">DELL AND BIOSIGN TECHNOLOGIES ENTER INTO GLOBAL HOSTING AGREEMENT<br /></span><span class="xn-location">TORONTO</span>, <span class="xn-chron">March 23</span> /CNW/ - Dell (Nasdaq: DELL) ("Dell") and Biosign Technologies Inc. (TSXV: BIO) ("Biosign") have entered into Hosting Agreements whereby Dell will host Biosign's UFIT and Healthanywhere platforms on a global basis. As a single partner for both hardware and support services, Dell will offer Biosign a fully-integrated, end-to-end solution that includes hardware, data center hosting and support. <a href="http://www.newswire.ca/en/releases/archive/March2011/23/c5683.html"><strong><strong><strong><strong>MORE>></strong></strong></strong></strong></a>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.comtag:blogger.com,1999:blog-3544246628583369041.post-45718145074860578452011-03-22T22:38:00.004-04:002011-04-29T11:22:58.219-04:00<span style="font-weight: bold;">CYNAPSUS ANNOUNCES PROPOSED ACQUISITION OF ADAGIO PHARMACEUTICALS AND PRIVATE PLACEMENT</span><strong><br />TORONTO, ONTARIO--(Marketwire - April 26, 2011) -</strong> <a name="top">Cynapsus Therapeutics Inc. (the "Corporation" or "Cynapsus") (CTH: TSX-V) is pleased to announce that it has entered into a preliminary agreement dated April 26, 2011 with Adagio Pharmaceuticals Ltd. ("Adagio") providing for the acquisition by Cynapsus of all of the issued and outstanding shares of Adagio in a share exchange (the "Proposed Transaction")</a>. <a href="http://www.cynapsus.ca/news.php?article=217"><strong><strong><strong><strong>MORE>></strong></strong></strong></strong></a>Mike Kostoffhttp://www.blogger.com/profile/14547550283861499028noreply@blogger.com